Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Veröffentlicht vonadmin 27. Juli 2020 Leisch, M; Egle, A; Greil, R; https://www.ncbi.nlm.nih.gov/pubmed/30795951